Porzio Life Sciences provides Aggregate Spend Regulatory Compliance software solutions for Pharmaceutical, Medical Device & Biotech companies comply with Affordable Care Act and Sunshine Act.
HomeProducts & ServicesMedia LibraryAbout UsContact UsSubscriber LoginGoToMeetingBlog
  • /Images-(1)/homepage-rotator/Intro-Slide.aspx
  • /Images-(1)/homepage-rotator/Porzio-Compliance-Digest.aspx
  • /Images-(1)/homepage-rotator/Porzio-Aggregate-Spend.aspx
  • /Images-(1)/homepage-rotator/Porzio-Licensing-Services.aspx
  • /Images-(1)/homepage-rotator/Porzio-Compliance-Modules.aspx
  • /Images-(1)/homepage-rotator/Significant-Loss-Assurance.aspx
  • /Images-(1)/homepage-rotator/ITD-HomepageSlider.aspx
  • /Images-(1)/homepage-rotator/Porzio-GST.aspx

Aggregate Spend Solutions and Regulatory Compliance Products

Porzio Life Sciences’ regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations, including PDMA, anti-kickback statutes, False Claims Act, FDA, OIG, Physician Payments Sunshine Act, Affordable Care Act and state aggregate spend compliance regulations.

Porzio AggregateSpendID® is an automated web-based solution for spend and samples data capture, tracking and reporting.  The system collects spend associated with sales representatives, senior executives, medical meetings, clinical trials, grants, eGrants, speaking fees, honoraria, etc.

Products and Services

Porzio AggregateSpendID®— Web-based system to track spend and samples directed towards healthcare providers and organizations - read more 

Porzio Compliance Digest— Searchable databases of sales and marketing statutes, regulations and pending legislation - read more 

Distribution Licensing— Identify, acquire and amend required state distribution licenses for drug and device manufacturers and distributors - read more 

Significant Loss Threshold Assurance—Formula-based sample accountability - read more  

Porzio Compliance Modules— "At-a-glance" information, regulations and agency rules - read more 


Porzio Life Sciences Celebrates National Customer Service Week 2014October 6-10, 2014
Porzio Life Sciences celebrates its 4th Annual National Customer Service Week by hosting five days of interactive internal events - Read more
The new office serving clients nationally and in Europe, will be led by Kevin Bell, Scott Chambers and Richard Oparil, intellectual property lawyers - Read more or Download (PDF)

Transparency is Sweeping the Globe 
Porzio Life Sciences, LLC (PorzioLS) announces the development of a Global Spend Transparency solution, Porzio GST™. The system provides an easy-to-use, configurable interface that will enable companies to capture and manage data elements necessary for meeting their reporting obligations in ex-US countries - Read more

Porzio Life Sciences Goes Global
International Life Sciences Transparency Database

Porzio Life Sciences, LLC, in collaboration with its French joint venture partner, Aubyn Life Sciences, announce the launch of the International Life Sciences Transparency Database (International Database).  The International Database contains invaluable guidance on non-US disclosure requirements pertaining to healthcare professional (HCP) and healthcare organization (HCO) payments - Read more
AdvaMed is the world’s largest medical technology association representing manufacturers of medical devices, diagnostics products, and medical information systems - Read more

Christine Bradshaw and Sarah Canberg Quoted in Article on the Sunshine Act’s Complexity
Christine N. Bradshaw, Associate of Porzio, Bromberg & Newman and Director of Regulatory and Compliance Services of Porzio Life Sciences, LLC and Sarah M. Canberg, Associate of Porzio, Bromberg & Newman and Manager of Regulatory and Compliance Services of Porzio Life Sciences, LLC are quoted in the Compliance Week article "Final Version Provides Little Relief for Complex Sunshine Act.” - Read more or go to Compliance Week

Scott Liebman and Christine Bradshaw Quoted in Article on the Finalization of the Sunshine Act 
Scott Liebman, Principal of Porzio, Bromberg & Newman and Vice President of Porzio Life Sciences and Christine Bradshaw, Associate of Porzio, Bromberg & Newman and Director of Regulatory and Compliance Services of Porzio Life Sciences are quoted in the article "The Sunshine Act is Finally Final" in the Pharma & Healthcare section of Forbes.com - Read more  or Go to Forbes

More News



read more 


Jeffrey Campbell, John Oroho, Brian Sharkey and Timothy Ayers are speaking at CBI's 12th Annual Pharmaceutical Compliance Congress in Washington D.C. on January 27-28, 2015 - Read more

Timothy Ayers and Michelle Axelrod Presenting an FDANews Webinar: The FDA Is Watching: What Twitter, Tradeshows and TV Have in Common 
The FDA's focus on promotional activities has expanded from magazine and TV ads to include Twitter, Facebook and more. FDA officials have been seen at medical meetings and industry trade shows, on the lookout for improper promotional materials. Takes place on Thursday, December 11, 2014 - Read more

Jennifer Romanski is speaking at the FDLI Introduction to Drug Law and Regulation: The Legal Framework for Drug Regulation in New Brunswick, NJ on December 11-12, 2014 - Read more

Timothy Ayers and Peter Zaudtke are attending the 56th ASH Annual Meeting and Exposition in San Francisco, CA on December 6-9, 2014 - Read more

CBI HCP Engagement, Data Validation and Reporting 
John Oroho is speaking at the CBI HCP Engagement, Data Validation and Reporting in Philadelphia, Pennsylvania on November 18-19, 2014 - Read more
Brian Sharkey is speaking at the European Healthcare Compliance Certification in Paris, France on November  17-20, 2014 and will also be speaking on Global Transparency Trends & Challenges at 2:40 pm on Tuesday, November 18, 2014 - Read more
John Oroho and Stephen Matthews are speaking at the CBI 5th Annual West Coast Compliance Congress in San Francisco, California on November 13-14, 2014 - Read more
John Oroho is speaking at the 15th Pharmaceutical Compliance Congress and Best Practices Forum in Washington, DC on November 3-5, 2014 - Read more

9th Porzio Compliance Forum held in collaboration with Seton Hall University School of Law's Center for Health & Pharmaceutical Law & Policy on Uncharted Compliance Waters 
Takes place on October 30, 2014 - Read more
Tim Ayers and John Oroho will be speaking at the CBI International Pharmaceutical Compliance Congress in Brussels, Belgium. Takes place on October 21-22, 2014 - Read more
Brian Sharkey is speaking at the American Conference Institutes 6th Annual Forum on: Sunshine Act, Open Payments, and Aggregate Spend Compliance in New York, NY.  Takes place on October 20-22, 2014 - Read more
Chrissy Bradshaw is presenting an Introduction on Sunshine Act as part of the Investigational Products Track – Betting on the Future: The Next Generation of Investigation Products at the 2014 ISPE Annual Meeting in Las Vegas, Nevada. Takes place on October 12-15, 2014 - Read more

More Events


New statutes and regulations lacking purpose and reason is causing over regulation of pharmaceutical industries - by Frank Fazio - Read more
Massachusetts based life sciences companies are at a disadvantage due to difficulties obtaining non-resident distribution licenses - by Frank Fazio -   Read more

by D. Jeffrey Campbell and Brian P. Sharkey - Read more or Download full White Paper

Industrial Site Recovery Act: An Environmental Consideration For New Jersey Life Sciences Facilities
Life sciences companies must consider the applicability and requirements of various environmental laws and regulations that
may apply to operations and transactions.  Lisa M. Bromberg and Thomas Spiesman - Read more

FDA’s Office of Prescription Drug Promotion (OPDP) Enforcement: A Summary of 2013 Warning and Untitled Letters
FDA’s Office of Prescription Drug Promotion (OPDP) issued a total of 24 enforcement letters to pharmaceutical manufacturers in 2013, 3 Warning Letters and 21 Untitled Letters - Read more

Getting the Deal Through: Life Sciences 2014 - United States Chapter Life Sciences in 24 Jurisdictions Worldwide
“In recent years, the United States has seen a significant increase in federal and state government-initiated enforcement actions against life sciences companies, many of which have resulted in multi-million, or even multi-billion, dollar settlements and penalties - by John Patrick Oroho and Brian P. Sharkey - Read more

Holland. The Original Cool.
The Dutch pharmaceutical industry has been ahead of the curve with respect to self-imposed transparency requirements - by D. Jeffrey Campbell and Brian P. Sharkey - Read more or download full article.